Shanghai Haohai Cuts Capital After Cancelling Over 3.2 Million H Shares

Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) has shared an announcement.

Shanghai Haohai Biological Technology Co., Ltd. has adjusted its share capital structure following earlier issuances of A and H shares, and now reports a total of 229,980,895 shares, consisting of 194,051,855 A shares and 35,929,040 H shares. The company’s registered capital has been correspondingly reset to RMB229,980,895, with A shares accounting for a larger proportion of its ordinary share capital.

The board has executed the cancellation of 3,212,800 repurchased H shares under previously approved mandates, reducing both total share count and registered capital. To reflect these changes, directors approved amendments to the Articles of Association, which took effect on 20 March 2026 without further shareholder approval, tightening the company’s capital base and slightly increasing the relative weighting of A shares in its equity structure.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

More about Shanghai Haohai Biological Technology Co., Ltd. Class H

Shanghai Haohai Biological Technology Co., Ltd. is a PRC-incorporated company listed in Hong Kong, with a share capital structure comprising A shares traded domestically and H shares listed in Hong Kong. Its capital base has evolved through initial public offerings of both H shares and domestic A shares, reflecting a dual-market financing strategy aimed at domestic and international investors.

Average Trading Volume: 141,921

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$10.01B

For detailed information about 6826 stock, go to TipRanks’ Stock Analysis page.